What is tirzepatide? Benefits, evidence and what independent lab tests show

Tirzepatide is a lab-made peptide that activates two gut-hormone receptors at once, GIP and GLP-1, to lower blood sugar and reduce appetite. It's FDA-approved and sold under two brand names — Mounjaro for type 2 diabetes and Zepbound for weight management — made by Eli Lilly. Most of what's sold on the research-peptide market under the name "tirzepatide" is not either of those products; it's an unbranded, unapproved version sold "for research use only," which is what most of this article, and our database, actually covers.

What tirzepatide is and how it works

Tirzepatide is a synthetic peptide engineered from the natural GIP hormone sequence, modified so it also activates GLP-1 receptors — making it a "dual agonist," the first approved drug of its kind. Both receptors sit on cells in the pancreas, gut, and brain, and both play a role in how the body manages blood sugar and hunger. Activating GLP-1 receptors slows stomach emptying, increases insulin release when blood sugar is high, and reduces glucagon (a hormone that raises blood sugar); the label also states that tirzepatide decreases food intake and reduces body weight (DailyMed, Mounjaro prescribing information, Eli Lilly).

Tirzepatide first won FDA approval in 2022 as Mounjaro, for improving blood sugar control in adults (and, later, adolescents 10 and older) with type 2 diabetes, and for reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk. It's sold under a second brand name, Zepbound, approved to reduce excess body weight and maintain weight loss in adults with obesity or with overweight plus a weight-related condition, and separately to treat moderate-to-severe obstructive sleep apnea in adults with obesity (DailyMed, Zepbound prescribing information). Same molecule, two labels, two different approved uses — which matters, because a lot of what circulates online blurs the two together.

Buyers on the research-peptide market shorten it to "tirz." In our data it's by far the most tested compound going, which tracks with how much attention it's gotten since Mounjaro and Zepbound both went mainstream.

What people use it for

What the research actually shows

Weight loss in people without diabetes

The trial that established tirzepatide as a weight-loss drug, SURMOUNT-1, followed 2,539 adults with obesity (or overweight plus a weight-related condition) who did not have diabetes, for 72 weeks in a randomized, double-blind, placebo-controlled design. At week 72, the highest dose studied produced an average weight loss of 20.9% versus 3.1% on placebo. In that group, 91% lost 5% or more of their body weight (35% on placebo) and 57% lost 20% or more (3% on placebo) (Jastreboff et al., NEJM 2022). Nearly all participants who had prediabetes at the start reverted to normal blood sugar by the end of the trial. This is the data behind Zepbound's approval.

Head-to-head against semaglutide in type 2 diabetes

SURPASS-2 put tirzepatide directly against semaglutide — the active ingredient in Ozempic — in 1,879 people with type 2 diabetes already on metformin, over 40 weeks. At week 40, A1c fell by 2.01 to 2.30 percentage points on tirzepatide (depending on dose) versus 1.86 on semaglutide, and every tirzepatide dose produced greater weight loss, with the highest dose losing 5.5 kg more than semaglutide (Frías et al., NEJM 2021). This is one of the more direct answers to "how does tirzepatide compare to semaglutide" that exists in the literature, though it's worth noting the trial wasn't blinded to which drug a patient received (only the tirzepatide dose was blinded), and it compared tirzepatide against a lower approved semaglutide dose than the one later used in Wegovy's own obesity trials.

Head-to-head against semaglutide in obesity

SURMOUNT-5 asked the obesity question directly: 751 adults with obesity but without type 2 diabetes were randomly assigned to tirzepatide or semaglutide, each at the highest dose a person could tolerate, for 72 weeks. Average weight loss was 20.2% on tirzepatide versus 13.7% on semaglutide (Aronne et al., NEJM 2025). The trial was open-label and funded by Eli Lilly, tirzepatide's maker, so read it with that in mind.

Cardiometabolic effects beyond weight and blood sugar

Both trials above also tracked secondary markers — waist circumference, blood pressure, fasting insulin, and lipid levels — and found improvements with tirzepatide beyond placebo or the comparator. In SURMOUNT-1, participants also showed a meaningfully larger drop in fat mass than in lean mass, and reported better physical-function scores. None of this is a claim that tirzepatide treats those conditions directly; it's what researchers measured alongside the primary weight and blood-sugar endpoints in these specific trials.

Why the two brand names matter for buyers

Because Mounjaro and Zepbound are the same molecule at different doses and with different labeled uses, a lot of online discussion treats "tirzepatide" as a single thing with a single purpose. It isn't, quite: the diabetes trials measured blood sugar first and weight as a secondary outcome, while the obesity trials measured weight first in people who, by design, didn't have diabetes. That distinction matters if you're trying to judge a specific claim against the specific trial it's based on — a claim about blood-sugar effects should point to Mounjaro-type diabetes data, and a claim about weight loss in someone without diabetes should point to SURMOUNT-1 or a similar obesity trial, not the other way around.

Side effects and risks

Tirzepatide's FDA labels carry a boxed warning: in rats, tirzepatide caused thyroid C-cell tumors, and it's unknown whether it does the same in humans. Both Mounjaro and Zepbound are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The most common side effects reported in the trials are gastrointestinal — nausea, diarrhea, vomiting, constipation, and stomach discomfort — occurring in a large majority of tirzepatide recipients versus a smaller share on placebo or comparator, mostly during the earliest weeks of treatment. Gallbladder-related events and, less commonly, pancreatitis have also been reported. None of the FDA-approved trials found an increased rate of confirmed medullary thyroid cancer in humans, but the studies weren't long enough or large enough to rule out a rare event.

That's the safety picture for the FDA-regulated product, made in an inspected facility with release testing on every batch. Research-labeled tirzepatide sold outside that system carries a different, additional set of risks: no manufacturing oversight, no guarantee the vial contains what the label says, and — as the sterility data below shows — no guarantee it's free of microbial contamination. "For research use only" is the label these products actually carry; nothing about that label implies the oversight an approved drug gets.

What the lab tests show

Today, our database includes 788 tirzepatide vials from 48 vendors, drawn from 396 lab reports dated March 2023 through September 2026. As of September 29, 2026, those reports spanned 15 labs, making tirzepatide the single most-tested compound we track, well over half of all vials in our data. Purity is generally strong: 784 vials have a purity result, and 709 of them (90%) came in at 99% or higher, with a median of 99.76%, and 0 came in under 95% purity.

Dose against label is more mixed. Across 761 vials with both a label amount and a measured amount, the median result ran 5.5% over label. 309 of those vials (41%) landed within ±5% of label, and as of September 29, 2026, 519 of 764 (68%) landed within ±10%. At the tails, 29 vials measured more than 10% under label and 9 of those more than 20% under; 51 measured more than 20% over, and 3 came in more than 50% over. 4 vials were reported empty. Altogether, 16 of the 788 tested vials (2.0%) counted as a failure under our scoring rules — empty, under 95% pure, more than 20% under label, or more than 50% over. As of September 29, 2026, the 15 failures then on file were spread across 10 of the 48 vendors, with no more than 3 failures at any single one, and 38 of the 48 vendors had no failed tirzepatide vial on file at all.

Vial size matters more for tirzepatide than for most compounds we track: larger vials ran noticeably closer to label than smaller ones. The bigger of the two most common sizes in our data landed within ±5% of label far more often than the smaller one, while one of the smaller sizes ran with a much higher median overfill and accounted for a disproportionate share of the under-label failures. If you're comparing a report against these overall numbers, check which size vial it covers, since the pattern isn't uniform across sizes.

Add-on testing tells its own story. As of September 29, 2026, of 64 endotoxin results, only 12 came back below the lab's detection limit — a smaller share than some other compounds in our data — and most numeric results clustered in a moderate range, with a handful running considerably higher; results aren't always reported in comparable units, so treat any single number with some caution. Sterility testing is rarer and more concerning: all 6 tirzepatide samples that were tested for total aerobic microbial count and total yeast/mold count failed at least one of the two counts. That's a very small, likely self-selected sample — probably vials someone already suspected were a problem — but it's a real result in our data, not a hypothetical, and it's the kind of thing an endotoxin or sterility add-on test is designed to catch.

As of September 29, 2026, 15 of the 48 vendors with tirzepatide results have enough reports (five or more) to be ranked specifically on this compound. Here's the live picture, which updates automatically as new reports come in:

For the full breakdown by vial size and by year, see the tirzepatide results page, which stays current, and our companion article, tirzepatide test results: what 788 lab-tested vials show.

What the data can't tell you

Lab reports answer narrow questions well: what's in this specific vial, at what purity, and how much of it. They can't tell you whether a vendor's manufacturing is consistent from batch to batch beyond what's actually been tested, whether a vial was stored correctly before it reached a buyer, or anything about a vendor's shipping speed, communication, or refund policy. A vendor with a strong record on paper can still ship a bad batch tomorrow; a report is a snapshot of the vials that were actually tested, not a permanent guarantee. That's also why report volume matters as much as the headline numbers — a vendor with two clean reports has told you less than one with twenty.

Buying smarter

A vendor's overall reputation says less than its specific record on this compound — check /peptides/tirzepatide directly rather than assuming a vendor's general score applies here, especially since dose accuracy swings by vial size. Before trusting any certificate of analysis a vendor posts, learn to read a peptide COA and check it against known fake-COA patterns — a posted certificate is not the same as an independent, buyer-commissioned lab report. If you want your own answer rather than someone else's, get your vial tested; given how often sterility failed in our small sample above, that add-on is worth considering specifically for tirzepatide. If a report comes back bad, stop using that batch, tell anyone who bought from the same run, bring it to the vendor, and submit it to VendorVerify so the next buyer has the data.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice, and research-labeled tirzepatide is sold for research use only.